_applied sciences_  
**Correction: [PERSON] et al. Microencapsulation of Bacteriophages for the Delivery to and Modulation of the Human Gut Microbiota through Milk and Cereal Products.**  
_Appl. Sci._**2022, 12, 6299**  
**[PERSON] 1,*, [PERSON] 1, [PERSON] 1, [PERSON] 2, [PERSON] 1 and [PERSON] 1,+**  
**Text Correction**  
With regard to the corrected Figure 6a and Table 2 (see above), the text following passages has been adjusted accordingly:  
(1) Abstract:  
Powdered capsules with particle sizes of \(\sim\)10 \(\upmu\)m and bacteriophage K5 titers of \(\sim\)10\({}^{7}\) plaque-forming units (pfu) g\({}^{-1}\) were obtained.  
(2) Section 2.4.2., Paragraph 1:  
The stability of the encapsulated bacteriophages (Section 2.2) with an initial bacteriophage titer \(N_{\mathrm{C}}\)* = 1.5 \(\times\) 10\({}^{7}\)-3.0 \(\times\) 10\({}^{7}\) pfu g\({}^{-1}\) was analyzed in simulated gastric fluid (SGF).  
(3) Section 3.4., Paragraph 8:  
The most important quality parameter of the capsules is the encapsulation efficiency, which was roughly 4% in this study (Table 2) (calculated with absolute bacteriophage titers; calculation with logarithmized bacteriophage titers would correspond to an encapsulation efficiency of around 80%).  
(4) Section 3.4., Paragraph 10:  
The capsules produced in this study had bacteriophage titers of around 10\({}^{7}\) pfu g\({}^{-1}\).  
The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.  
**Reference**  
1. [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON] Microencapsulation of Bacteriophages for the Delivery to and Modulation of the Human Gut Microbiota through Milk and Cereal Products. _Appl. Sci._**2022**, _12_, 6299. [CrossRef]  
**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.  
\begin{table}
\begin{tabular}{c c c} \hline \hline
**Capsules Characteristics** & **Alginate + Micellar** & **Alginate + Whey Protein** \\  & **Casein Capsules** & **Isolate Capsules** \\ \hline Humidity (\%) & 8.70 \(\pm\) 0.86 & 9.43 \(\pm\) 0.32 \\ Water activity (-) & 0.15 \(\pm\) 0.03 & nd. * \\ Particle diameter \(d_{10,3}\) (\(\upmu\)m) & 3.6 \(\pm\) 1.2 & 5.1 \(\pm\) 0.4 \\ Particle diameter \(d_{50,3}\) (\(\upmu\)m) & 8.9 \(\pm\) 0.7 & 12.0 \(\pm\) 1.9 \\ Particle diameter \(d_{90,3}\) (\(\upmu\)m) & 17.5 \(\pm\) 4.4 & 46.2 \(\pm\) 2.9 \\ Encapsulation efficiency (\%) & 4.2 \(\pm\) 2.1 ** & 3.6 \(\pm\) 2.1 *** \\ Bacteriophage titer (pfu g\({}^{-1}\)) & (3.4 \(\pm\) 1.7) \(\times\) 10\({}^{7}\) & (1.6 \(\pm\) 0.9) \(\times\) 10\({}^{7}\) \\ \hline \hline \end{tabular}  
* n.d.—not determined. ** Values inserted into Equation (3): \(N_{\mathrm{S}}\) = (3.6 \(\pm\) 0.3) \(\times\) 10\({}^{7}\) pfu mL\({}^{-1}\), \(N_{\mathrm{C}}\)* (1.5 \(\pm\) 0.7) \(\times\) 10\({}^{6}\) pfu mL\({}^{-1}\). *** Values inserted into Equation (3): \(N_{\mathrm{S}}\) = (2.0 \(\pm\) 0.1) \(\times\) 10\({}^{7}\) pfu mL\({}^{-1}\), \(N_{\mathrm{C}}\)* (7.3 \(\pm\) 4.1) \(\times\) 10\({}^{5}\) pfu mL\({}^{-1}\).  
\end{table}
Table 2: Analysis of the bacteriophage K5 capsules regarding physical and biological parameters. Capsules were mainly composed of sodium alginate and milk protein (either micellar casein or whey protein isolate).